Loading...
  • vitro
  • The iron liposomes were unstable in vitro and thus not studied further. (uzh.ch)
  • In vitro incubations with human plasma, followed by high-pressure liquid chromatography (HPLC) separation of the Gd-DTPASA and Mn-DTPASA liposomes showed that after an incubation period of 24 hours, only 4% of the gadolinium was bound to the plasma proteins, whereas, with the Mn-DTPASA liposomes, a transfer of 40% manganese was seen. (uzh.ch)
  • We reconstituted the DivL-CckA complex on liposomes in vitro and found that DivL directly controls the CckA kinase/phosphatase switch, and that stimulation of either CckA catalytic activity depends on the second of its two PAS domains. (pnas.org)
  • Herein, we introduce a new liposome-based IVC system consisting of a liposome, the protein synthesis using recombinant elements (PURE) system and a fluorescence-activated cell sorter (FACS) used as a microcompartment, in vitro protein synthesis system, and high-throughput screen, respectively. (hindawi.com)
  • Liposome-based IVC is characterized by in vitro protein synthesis from a single copy of a gene in a cell-sized unilamellar liposome and quantitative functional evaluation of the synthesized proteins. (hindawi.com)
  • particles
  • A method of fabricating hydrogel particles within liposomes, which entails: a) encapsulating an effective amount of each of one or more hydrogel substances and one or more release agents in liposomes in a liquid medium, b) removing any unencapsulated hydrogel substances and release agents from the liquid. (google.co.uk)
  • 5. The hydrogel particles of claim 1, wherein said liposomes are unilamellar liposomes. (google.co.uk)
  • 7. The hydrogel particles of claim 1, wherein said liposomes are formed from a lipid material selected from the group selected from the group consisting of phosphatidyl ethers, phosphatidyl esters, phosphatidyl ethanolamine, phosphatidylcholine, glycerides, cerebrosides, gangliosides, sphingomyelin, steroids and cholesterol. (google.co.uk)
  • The present invention relates to a method for fabricating hydrogel particles having an accurately controlled size using liposomes. (google.co.uk)
  • 9 . The process according to claim 1 , characterised in that the carrier particles, especially liposomes, have a substantially uniform size in the range between about 1 and about 50 μm, preferably in the range between about 1 and about 30 μm. (google.es)
  • 10 . The process according to claim 9 , characterised in that the carrier particles, especially liposomes, have a substantially uniform size in the range between about 20 and 30 μm diameter for application to the trachea, in the range between about 10 and 20 μm diameter for application to the bronchi and between about 1 and 6 nm, especially between 2 and 5 μm, diameter for application to the alveoli. (google.es)
  • drug
  • For topical applications on skin, specialized lipids like phospholipids and sphingolipids may be used to make drug-free liposomes as moisturizers, and with drugs such as for anti-ultraviolet radiation applications. (wikipedia.org)
  • and a surfactant which interacts with the liposomes to reduce drug encapsulation and modulate drug release from the liposomes. (freepatentsonline.com)
  • and wherein the free drug comprises between about 5 and about 50% of a total of free drug and liposome encapsulated drug. (freepatentsonline.com)
  • 11. The composition of claim 3, wherein the surfactant causes an increase in drug release rate from the liposomes of about 5% to 50% as measured by an IVR assay. (freepatentsonline.com)
  • These liposomes work to deliver drug by diffusion rather than by direct cell fusion. (wikipedia.org)
  • Another strategy for liposome drug delivery is to target endocytosis events. (wikipedia.org)
  • least
  • 2 . The process of claim 1 , characterised in that said particulate carrier comprises at least one of a liposome preparation, a microsphere preparation, a nanoparticle preparation, a Large Porous Particle preparation or a laser-pulse polymer coated molecule preparation. (google.es)
  • 3 . The process according to claim 1 , characterised in that at least the greatest part of said agent is encapsulated inside the carrier, especially a liposome or microsphere carrier. (google.es)
  • preparation
  • 11 . The process according to claim 1 , characterised in that the carrier, especially liposome, preparation releases the agent over an extended time period, preferably an extended time period of several hours duration. (google.es)
  • 12 . The process according to claim 11 , characterised in that the carrier, especially liposome, preparation releases the agent at approximately the same release rate over the release time period. (google.es)